Sjögren's disease is a chronic systemic autoimmune disorder that primarily affects moisture-producing glands, leading to dryness in the eyes and mouth. It is often miscategorized as a rare disease, but some sources suggest that it is the second most common rheumatological disease in adults in the United States. We estimate that in 2024, there were 653.4 thousand prevalent cases of Sjögren’s disease across the US, 5EU, and Japan markets, and forecast that number to increase to 700.3 thousand cases by 2030.

Our experts have curated a new disease intelligence report specific to Sjögren's disease available for purchase now. This PDF report with accompanying patient-based excel forecast was created to answer key questions such as:

• How much market share will dazodalibep capture upon approval?
• What is the addressable patient population within Sjögren's disease?
• What are the unmet needs within this space?
• What is the landscape of pipeline drugs- who do we need to be paying attention to?
• What are the strengths and weaknesses of VAY-736 (or other drugs!) in Sjögren's disease?
• What future trends are analysts seeing for these patients?

To learn more, please contact us here for a table of contents! If you are a current Datamonitor subscriber, this report can be accessed here.